Tag - Charles Duncan

Cantor cuts Otonomy PT to $6 from $13

Cantor Fitzgerald slashed its price target for Otonomy (NASDAQ:OTIC) to $6 from $13 but maintained its “overweight” rating, after the company announced that the Phase 3 study of OTIVIDEX in Ménière’s disease did not...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.